| CAS NO: | 163706-36-3 |
| 包装 | 价格(元) |
| 10 mM * 1 mL in Water | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| 生物活性 | Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective plateletP2Y12antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecificGPR17antagonist[1][2]. | ||||||||||||||||
| IC50& Target |
| ||||||||||||||||
| 体外研究 (In Vitro) | Cangrelor tetrasodium is the only potent intravenous direct and specific adenosine diphosphate (ADP) P2Y12 receptor antagonist[1]. | ||||||||||||||||
| 体内研究 (In Vivo) | Cangrelor tetrasodium (10 mg/kg) not only significantly decreases BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreases the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice[2]. | ||||||||||||||||
| Clinical Trial | |||||||||||||||||
| 分子量 | 864.29 | ||||||||||||||||
| 性状 | Solid | ||||||||||||||||
| Formula | C17H21Cl2F3N5Na4O12P3S2 | ||||||||||||||||
| CAS 号 | 163706-36-3 | ||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 储存方式 | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | ||||||||||||||||
| 溶解性数据 | In Vitro: H2O : 125 mg/mL(144.63 mM;Need ultrasonic) DMSO : 12.5 mg/mL(14.46 mM;ultrasonic and warming and heat to 80℃) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
